216 related articles for article (PubMed ID: 31446244)
1. Development of novel chromeno[4,3-c]pyrazol-4(2H)-one derivates bearing sulfonylpiperazine as antitumor inhibitors targeting PI3Kα.
Yin Y; Sha S; Wu X; Wang SF; Qiao F; Song ZC; Zhu HL
Eur J Med Chem; 2019 Nov; 182():111630. PubMed ID: 31446244
[TBL] [Abstract][Full Text] [Related]
2. Development of novel chromeno[4,3-c]pyrazol-4(2H)-one derivates containing piperazine as inhibitors of PI3Kα.
Yin Y; Zhou Y; Sha S; Wu X; Wang SF; Qiao F; Song ZC; Zhu HL
Bioorg Chem; 2019 Nov; 92():103238. PubMed ID: 31499259
[TBL] [Abstract][Full Text] [Related]
3. Novel 4-aminoquinazoline derivatives induce growth inhibition, cell cycle arrest and apoptosis via PI3Kα inhibition.
Fan YH; Ding HW; Liu DD; Song HR; Xu YN; Wang J
Bioorg Med Chem; 2018 May; 26(8):1675-1685. PubMed ID: 29475582
[TBL] [Abstract][Full Text] [Related]
4. Design, synthesis and biological evaluation of novel chromeno[4,3-c]pyrazol-4(2H)-one derivates containing sulfonamido as potential PI3Kα inhibitors.
Yin Y; Hu JQ; Wu X; Sha S; Wang SF; Qiao F; Song ZC; Zhu HL
Bioorg Med Chem; 2019 Jun; 27(11):2261-2267. PubMed ID: 31029551
[TBL] [Abstract][Full Text] [Related]
5. Discovery of Chromeno[4,3-c]pyrazol-4(2H)-one Containing Carbonyl or Oxime Derivatives as Potential, Selective Inhibitors PI3Kα.
Lu L; Sha S; Wang K; Zhang YH; Liu YD; Ju GD; Wang B; Zhu HL
Chem Pharm Bull (Tokyo); 2016 Nov; 64(11):1576-1581. PubMed ID: 27581755
[TBL] [Abstract][Full Text] [Related]
6. Discovery of novel 1,3,5-triazine derivatives as potent inhibitor of cervical cancer via dual inhibition of PI3K/mTOR.
Hu J; Zhang Y; Tang N; Lu Y; Guo P; Huang Z
Bioorg Med Chem; 2021 Feb; 32():115997. PubMed ID: 33440319
[TBL] [Abstract][Full Text] [Related]
7. Synthesis and anticancer evaluation of novel 1H-benzo[d]imidazole derivatives of dehydroabietic acid as PI3Kα inhibitors.
Yang YQ; Chen H; Liu QS; Sun Y; Gu W
Bioorg Chem; 2020 Jul; 100():103845. PubMed ID: 32344183
[TBL] [Abstract][Full Text] [Related]
8. Alkylsulfonamide-containing quinazoline derivatives as potent and orally bioavailable PI3Ks inhibitors.
Hei YY; Zhang SQ; Feng Y; Wang J; Duan W; Zhang H; Mao S; Sun H; Xin M
Bioorg Med Chem; 2019 Oct; 27(20):114930. PubMed ID: 31176568
[TBL] [Abstract][Full Text] [Related]
9. Design, synthesis and biological evaluation of novel series of 2H-benzo[b][1,4]oxazin-3(4H)-one and 2H-benzo[b][1,4]oxazine scaffold derivatives as PI3Kα inhibitors.
Dong FD; Liu DD; Deng CL; Qin XC; Chen K; Wang J; Song HR; Ding HW
Bioorg Med Chem; 2018 Aug; 26(14):3982-3991. PubMed ID: 29937355
[TBL] [Abstract][Full Text] [Related]
10. Discovery and synthesis of a novel series of potent, selective inhibitors of the PI3Kα: 2-alkyl-chromeno[4,3-c]pyrazol-4(2H)-one derivatives.
Yin Y; Wu X; Han HW; Sha S; Wang SF; Qiao F; Lu AM; Lv PC; Zhu HL
Org Biomol Chem; 2014 Dec; 12(45):9157-65. PubMed ID: 25296388
[TBL] [Abstract][Full Text] [Related]
11. Design and Synthesis of Coumarin Derivatives as Novel PI3K Inhibitors.
Ma CC; Liu ZP
Anticancer Agents Med Chem; 2017; 17(3):395-403. PubMed ID: 26902599
[TBL] [Abstract][Full Text] [Related]
12. Synthesis, biological evaluation and structure-activity relationship of a novel class of PI3Kα H1047R mutant inhibitors.
Zhang N; Yu Z; Yang X; Zhou Y; Wang J; Zhang SL; Wang MW; He Y
Eur J Med Chem; 2018 Oct; 158():707-719. PubMed ID: 30245395
[TBL] [Abstract][Full Text] [Related]
13. Discovery of 2-(2-aminopyrimidin-5-yl)-4-morpholino-N-(pyridin-3-yl)quinazolin-7-amines as novel PI3K/mTOR inhibitors and anticancer agents.
Peng W; Tu ZC; Long ZJ; Liu Q; Lu G
Eur J Med Chem; 2016 Jan; 108():644-654. PubMed ID: 26731167
[TBL] [Abstract][Full Text] [Related]
14. Design, synthesis, and biological evaluation of novel 3-substituted imidazo[1,2-a]pyridine and quinazolin-4(3H)-one derivatives as PI3Kα inhibitors.
Fan YH; Li W; Liu DD; Bai MX; Song HR; Xu YN; Lee S; Zhou ZP; Wang J; Ding HW
Eur J Med Chem; 2017 Oct; 139():95-106. PubMed ID: 28800461
[TBL] [Abstract][Full Text] [Related]
15. Potent inhibitors of phosphatidylinositol 3 (PI3) kinase that have antiproliferative activity only when delivered as prodrug forms.
O'Brien NJ; Amran S; Medan J; Cleary B; Deady LW; Jennings IG; Thompson PE; Abbott BM
ChemMedChem; 2013 Jun; 8(6):914-8. PubMed ID: 23568455
[TBL] [Abstract][Full Text] [Related]
16. Synthesis and biological evaluation of novel 2,3-dihydrochromeno[3,4-d]imidazol-4(1H)-one derivatives as potent anticancer cell proliferation and migration agents.
Han X; Luo J; Wu F; Hou X; Yan G; Zhou M; Zhang M; Pu C; Li R
Eur J Med Chem; 2016 May; 114():232-43. PubMed ID: 26994691
[TBL] [Abstract][Full Text] [Related]
17. Synthesis and antitumor activities evaluation of m-(4-morpholinoquinazolin-2-yl)benzamides in vitro and in vivo.
Wang XM; Xin MH; Xu J; Kang BR; Li Y; Lu SM; Zhang SQ
Eur J Med Chem; 2015; 96():382-95. PubMed ID: 25911625
[TBL] [Abstract][Full Text] [Related]
18. Discovery of 4-phenyl-2H-benzo[b][1,4]oxazin-3(4H)-one derivatives as potent and orally active PI3K/mTOR dual inhibitors.
Yan G; Pu C; Lan S; Zhong X; Zhou M; Hou X; Yang J; Shan H; Zhao L; Li R
Eur J Med Chem; 2019 Sep; 178():667-686. PubMed ID: 31228810
[TBL] [Abstract][Full Text] [Related]
19. Design, synthesis and biological evaluation of novel 4-aminoquinazolines as dual target inhibitors of EGFR-PI3Kα.
Ding HW; Deng CL; Li DD; Liu DD; Chai SM; Wang W; Zhang Y; Chen K; Li X; Wang J; Song SJ; Song HR
Eur J Med Chem; 2018 Feb; 146():460-470. PubMed ID: 29407971
[TBL] [Abstract][Full Text] [Related]
20. Structural investigations on coumarins leading to chromeno[4,3-c]pyrazol-4-ones and pyrano[4,3-c]pyrazol-4-ones: New scaffolds for the design of the tumor-associated carbonic anhydrase isoforms IX and XII.
Bonardi A; Falsini M; Catarzi D; Varano F; Di Cesare Mannelli L; Tenci B; Ghelardini C; Angeli A; Supuran CT; Colotta V
Eur J Med Chem; 2018 Feb; 146():47-59. PubMed ID: 29407972
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
